Conditions: Non-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer Squamous Cell Non-Metastatic Non-Small Cell Lung Cancer
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1
Healthy volunteers: no

Brief summary:
To determine the rate of pathologic complete responses (pCR) at the time of definitive surgical resection of non-small cell lung cancer (NSCLC)

Detailed description:
Participants in this study will have a lung mass and are undergoing a procedure to determine if they have non-small cell lung cancer that could be removed surgically. If confirmed to have non-small cell lung cancer that can be surgically removed, he or she may be able to continue as a possible participant in this study.

The purpose of this study is to determine whether neoadjuvant chemotherapy (chemotherapy that is given before surgery) will improve the amount of time a participant is free from disease in people with non-metastatic (has not spread from the original site) non-small cell lung cancer. The chemotherapy medications that will be used in this study are cisplatin and pemetrexed or cisplatin and gemcitabine and have been shown to be effective in patients with non-small cell lung cancer.

Arms:
arm 1: Cisplatin on day 1 and pemetrexed on day 1, 1 cycle = 21 days, deliver 4 neoadjuvant cycles arm 2: Cisplatin on day 1 and gemcitabine on days 1 and 8, 1 cycle = 21 days, deliver 4 neoadjuvant cycles

Interventions: intervention 1: Cisplatin intervention 2: Pemetrexed intervention 3: Gemcitabine
Intervention descriptions: intervention 1: Alkylating antineoplastic agent (Chemotherapy) intervention 2: Antimetabolite antineoplastic agent (Chemotherapy) intervention 3: Antimetabolite antineoplastic agent (Chemotherapy)

Protocol document: